141 results on '"D. Robesti"'
Search Results
2. The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
3. Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
4. Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
5. Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
6. The added value of concomitant systematic biopsy in predicting biochemical recurrence after radical prostatectomy in patients with prostate cancer diagnosed by MRI-targeted biopsy
7. Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
8. Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?
9. Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data
10. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series
11. A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
12. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
13. Long-term outcomes of clinically node-positive prostate cancer patients treated with radical prostatectomy as part of a multimodal treatment: patterns of recurrence and impact on competing-risk mortality
14. Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
15. The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer
16. A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes
17. Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series
18. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database
19. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database
20. Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series
21. Is focal ablation as effective as hemi-ablation? Analysis of treatment patterns over 12 years from a high volume centre for focal therapy
22. The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
23. Are men with low risk prostate cancer but high PIRADS score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
24. When to omit lymphadenectomy during radical prostatectomy in patients with clinical localized prostate cancer: A clinical net benefit analysis weighting staging accuracy, risk of morbidity and life expectancy
25. Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
26. Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
27. A positive PSMA PET/CT predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
28. Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
29. The added value of concomitant systematic biopsy in predicting biochemical recurrence after radical prostatectomy in patients with prostate cancer diagnosed by MRI-targeted biopsy
30. The implementation of a prospective standardized postoperative complication system according to the EAU guidelines is associated with a decrease in the rate of adverse postoperative outcomes over time
31. Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND
32. Oncologic outcomes of patients with incidental prostate cancer: Can we rely on multiparametric mri to exclude aggressive prostate cancer?
33. Exploring the effect of metastasis directed therapy on progression patterns of patients with positive 68Ga-PSMA PET/CT and biochemical recurrence from prostate cancer
34. Does prostate cancer family history have an impact on active surveillance adherence in men with low- or favourable intermediate risk disease?
35. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211
36. Is there an impact of the center performing baseline multiparametric MRI on active surveillance outcomes in prostate cancer patients?
37. Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy
38. Impact of radiologist expertise on PI-RADS distribution and detection of clinically significant prostate cancer: Results from a single, high volume center
39. When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification
40. Is there a preferential lymph node metastasis pathway in prostate cancer according to the site of the index lesion at multiparametric MRI? A topographic mapping study
41. Assessing the impact of TURBT specimens review by a dedicated uropathologist on clinical decision making process: Results from a single tertiary referral center
42. A patient tailored follow-up protocol for men with prostate cancer managed with active surveillance with the use of multiparametric magnetic resonance imaging: Identifying predictors of early and late reclassification in a large single institution cohort
43. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics
44. Reliability of 68Ga-PSMA PET/CT in assessing real nodal burden in men with cN1 disease: clinical implications for patient counselling and multi-modal treatments
45. Histological variants of prostate cancer are under-reported in prostate biopsies assessed outside tertiary referral centers. a plea for biopsy review for optimal patient management
46. Assessing the role of frailty status on oncologic and functional outcomes in patients treated with robot-assisted radical prostatectomy for localized prostate cancer
47. The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to the type preoperative staging. a comparison between 68ga-PSMA-PET versus conventional imaging in a large, multi-institutional study
48. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy
49. Impact of Prostate Imaging Quality (PI-QUAL) score on the detection of clinically significant prostate cancer in men undergoing MRI-targeted biopsy
50. The prognostic role of 68Ga-PSMA PET/CT and the impact of metastasis-directed therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.